Bortezomib-Induced Blepharitis: A Case Report_ Crimson Publishers

 Bortezomib-Induced Blepharitis: A Case Report by Kamal AlZahran* in Surgical Medicine Open Access Journal_ Surgical Medicine Open Access Journal

Abstract
Multiple myeloma is characterized by a neoplastic proliferation of plasma cells in the bone marrow producing a monoclonal immunoglobulin and resulting in extensive skeletal destruction. One of the used treatment regimens for MM being the VCD protocol (Velcade® or Bortezomib, Cyclophosphamide and Dexamethasone) [1,2]. Bortezomib is a proteasome inhibitor that acts by disrupting the cell cycle and inducing apoptosis, usually tolerated in the outpatient settings with manageable toxicities, the most common ones being peripheral neuropathy and thrombocytopenia [1,2]. Blepharitis is an inflammatory condition of the eyelid margin causing ocular and visual discomfort leading to formation of chalazia (lipogranulomatous lesions) [3,4]. It is classified as anterior blepharitis when it involves the eyelid skin and the follicules and posterior when it involves the Meibomian glands; it is usually associated with staphylococcus aureus colonization, infestation with parasites, Meibomian gland dysfunction, rosacea, systemic use of docetaxel [3,4]. Bortezomib has been associated with ocular complications but it has not been well characterized. We herein present a case of Bortezomib-induced blepharitis that has been successfully treated

https://crimsonpublishers.com/smoaj/fulltext/SMOAJ.000561.php

Crimson Publishers: https://crimsonpublishers.com/

For more articles in Surgical Medicine Open Access Journal,
Please click on below link: https://crimsonpublishers.com/smoaj/